Vortioxetine

證據等級: L5

預測適應症: 5 個

Vortioxetine: From Major Depressive Disorder to Neurotic Disorder

One-Sentence Summary

Vortioxetine is a multimodal serotonergic antidepressant reported in the literature as approved for Major Depressive Disorder (MDD); no local regulatory indication text is available since the product is not currently marketed. The TxGNN model's top-ranked prediction is Neurotic Disorder, but this specific label is currently supported by only 1 clinical trial and 1 publication, both of low direct relevance.

Quick Overview

Item	Content
Original Indication	Not documented in the regulatory dossier (no licenses on file); per supporting literature (PMID 29189941), Vortioxetine is approved for Major Depressive Disorder
Predicted New Indication	Neurotic Disorder
TxGNN Prediction Score	99.24%
Evidence Level	L4
Germany Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data for this candidate is not available in the evidence pack (original_moa: [Data Gap]). Based on the supporting literature retrieved for this candidate (PMID 25016186, PMID 29189941), Vortioxetine is a multimodal antidepressant acting as a serotonin transporter (SERT) inhibitor combined with 5-HT3, 5-HT7, and 5-HT1D receptor antagonism, 5-HT1B partial agonism, and 5-HT1A agonism — increasing serotonergic, noradrenergic, dopaminergic, cholinergic, histaminergic, and glutamatergic neurotransmission in brain regions implicated in mood regulation. Its efficacy in Major Depressive Disorder has been demonstrated across multiple Phase 3 registration trials cited elsewhere in this evidence pack.

"Neurotic disorder" is a broad, largely obsolete diagnostic category historically encompassing anxiety, depressive, and somatoform symptom clusters. There is conceptual overlap between this category and MDD, which provides a plausible — but non-specific — mechanistic rationale for TxGNN's prediction. However, the evidence pack itself flags this: the only linked trial (NCT04446039) is a large real-world retrospective cohort comparing antidepressants generally, not a study designed around "neurotic disorder" as an inclusion criterion, and the only linked publication is a single case-based review of "neurotic depression" (a related but distinct label). The model's own rationale field explicitly notes the evidence is "insufficient to support a specific clinical decision" for this label.

Note: Within this same evidence pack, the rank-3 candidate — Melancholia — is substantially better supported (6 completed Phase 3 RCTs directly testing Vortioxetine in MDD, evidence level L1, recommendation "Proceed with Guardrails"). Melancholia is a recognized severe/biological MDD subtype and may represent a more actionable repurposing signal than the top-ranked "Neurotic Disorder" label; this should be considered when prioritizing next steps.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04446039	N/A	Completed	370,212	Real-world retrospective cohort study using nationwide claims data comparing medication utilization patterns and adverse-outcome risk across commonly used antidepressants; not designed around "neurotic disorder" specifically (relevance grade C).

Literature Evidence

PMID	Year	Type	Journal	Key Findings
31006795	2019	Review (case report)	Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova	Case report on neurotic depression, discussing personal predisposition and clinical features; advocates a combined antidepressant + CBT approach. Does not directly evaluate Vortioxetine.

Germany Market Information

Not currently marketed in Germany — no product authorizations are on file for this drug.

Safety Considerations

Please refer to the package insert for safety information.

(Note: the TFDA label/warnings data required for a full S1 safety review is currently a blocking data gap in this evidence pack — see next steps below.)

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked TxGNN prediction ("Neurotic Disorder") is supported only by a non-specific real-world cohort study and a single case-report-level review, corresponding to evidence level L4. This is insufficient to justify progression beyond initial screening for this specific indication label.

To proceed, the following is needed:

Retrieve TFDA/BfArM label warnings and contraindications (currently a Blocking data gap; required before any S1 safety assessment)
Obtain confirmed mechanism-of-action documentation from DrugBank (currently a High-severity data gap)
Clarify whether "Neurotic Disorder" maps to a modern, actionable diagnostic entity, or whether effort should instead be redirected to the better-evidenced Melancholia candidate (L1, 6 Phase 3 RCTs) identified in the same prediction batch
If pursuing Neurotic Disorder specifically, seek trials or studies with inclusion criteria matching this diagnostic label rather than general antidepressant-comparison cohorts
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.